腎去神經支配市場－全球產業規模、佔有率、趨勢、機會和預測，按技術、產品、治療領域、最終用戶、地區和競爭細分，2020 年至 2030 年

2024 年全球腎臟去神經支配市場價值為 5.1234 億美元，預計到 2030 年將達到 8.7385 億美元，預測期內的複合年成長率為 9.45%。全球腎臟去神經支配市場正在經歷顯著成長，這得益於高血壓盛行率的上升以及藥物治療在治療難治性病例方面的局限性。腎臟去神經支配透過針對腎動脈中過度活躍的交感神經提供了一種新方法，為對傳統藥物反應不佳的患者提供了替代治療方法。人口老化加劇、人們對非藥物治療方案認知的提高以及導管技術的進步（提高了手術的安全性和有效性）都推動了這一需求。射頻、超音波和化學消融方法的創新擴大了治療範圍，使該手術對醫療保健提供者和尋求長期解決血壓失控問題的患者更具吸引力。市場擴張也受到越來越多的臨床試驗的影響，這些臨床試驗證實了腎去神經術在降低不同患者群體（包括未服用抗高血壓藥物的患者）血壓方面的益處。醫院、專科診所和門診手術中心擴大將這種療法納入其心血管護理方案。隨著監管部門的批准日益廣泛，以及醫療保健系統致力於減輕慢性高血壓的經濟負擔，腎去神經術預計將在全球範圍內獲得更大的發展。隨著研發投入的增加和醫生認知度的提高，市場有望穩定成長。

關鍵市場促進因素

高血壓盛行率上升

主要市場挑戰

缺乏長期臨床資料

主要市場趨勢

技術進步有利於超音波和微輸注

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球腎臟去神經支配市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依技術分類（超音波消融、射頻消融、藥物消融、微灌注）
  • 依產品（導管、單電極導管、多電極導管、射頻產生器、其他）
  • 依治療領域（高血壓、心臟衰竭、糖尿病、腎衰竭、其他）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 依技術
  • 按產品
  • 按治療領域
  • 按最終用戶
  • 按地區

第6章：北美腎臟去神經市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲腎臟去神經市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太腎臟去神經市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲腎臟去神經市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲腎臟去神經市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 併購
• 產品發布

第 13 章：競爭格局

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc. (Otsuka Holdings)
• Cardiosonic Ltd
• Mercator MedSystems, Inc
• Renal Dynamics Limited

第 14 章：策略建議

第15章調查會社について,免責事項

Global Renal Denervation Market was valued at USD 512.34 Million in 2024 and is expected to reach USD 873.85 Million by 2030 with a CAGR of 9.45% during the forecast period. The global renal denervation market is witnessing significant growth driven by the increasing prevalence of hypertension and the limitations of pharmacological therapies in managing resistant cases. Renal denervation offers a novel approach by targeting the overactive sympathetic nerves in the renal arteries, providing an alternative treatment for patients who fail to respond adequately to conventional medications. The demand is supported by a growing aging population, rising awareness of non-pharmacologic treatment options, and advancements in catheter-based technologies that enhance procedural safety and efficacy. Innovation in radiofrequency, ultrasound, and chemical-based ablation methods has expanded the scope of treatment, making the procedure more appealing to healthcare providers and patients seeking long-term solutions to uncontrolled blood pressure. Market expansion is also influenced by the growing number of clinical trials validating the benefits of renal denervation in reducing blood pressure across various patient groups, including those not on antihypertensive drugs. Hospitals, specialty clinics, and ambulatory surgical centers are increasingly incorporating this therapy into their cardiovascular care protocols. As regulatory approvals become more widespread and healthcare systems seek to reduce the economic burden of chronic hypertension, renal denervation is expected to gain more traction globally. The market is positioned for steady growth with increasing investments in R&D and expanding awareness among physicians.

Key Market Drivers

Rising Prevalence of Hypertension

The rising prevalence of hypertension is a key factor influencing the growth of the global renal denervation market. Hypertension has become one of the most common chronic health conditions worldwide, driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, obesity, and increased stress levels. For instance, according to WHO 2023, about 1.28 billion adults aged 30-79 suffer from hypertension globally, with two-thirds living in low- and middle-income countries. Nearly 46% are unaware of their condition, only 42% receive treatment, and just 21% have it under control. Reducing hypertension prevalence by 33% by 2030 remains a global health target. As the number of individuals diagnosed with high blood pressure continues to climb, so does the demand for more effective and sustainable treatment options. A significant proportion of patients experience resistant hypertension, where blood pressure remains high despite the use of three or more antihypertensive medications. This segment presents a major challenge in clinical practice and highlights the need for alternative solutions beyond drug therapy. Renal denervation has emerged as a promising intervention in such cases, offering a minimally invasive, device-based treatment that directly targets the overactive renal sympathetic nerves. For instance, according to the CDC, in 2022, high blood pressure was a primary or contributing factor in 685,875 deaths in the U.S. Around one in five COVID-19-related deaths occurred in individuals with a history of hypertensive disease, highlighting its significant role in overall mortality. The growing population of patients with uncontrolled or drug-intolerant hypertension makes renal denervation an attractive option for healthcare providers seeking to improve long-term outcomes. As awareness grows about the limitations of current pharmacological approaches, interest in non-pharmacologic interventions is rising. This trend is positioning renal denervation as an increasingly important tool in the global effort to manage hypertension more effectively and reduce its associated health risks.

Key Market Challenges

Lack of long-term clinical data

The lack of long-term clinical data remains one of the most significant challenges impacting the growth and acceptance of the global renal denervation market. While recent clinical trials have shown encouraging short-term results in reducing blood pressure among patients with resistant hypertension, healthcare providers and regulatory bodies still seek more comprehensive, long-term evidence to support widespread clinical adoption. Decision-makers in healthcare systems are cautious about incorporating device-based interventions without robust data that demonstrate sustained efficacy and safety over extended periods. Short-term reductions in blood pressure are promising, but the true value of renal denervation lies in its ability to maintain control over time and reduce the risk of major cardiovascular events. Without long-term follow-up data, it is difficult to evaluate whether the initial benefits translate into lasting improvements in patient outcomes, such as reduced incidence of stroke, heart attack, or kidney failure. The absence of extended trial data also creates uncertainty around patient selection, optimal procedural techniques, and the durability of nerve ablation. This uncertainty can hinder physician confidence, delay reimbursement decisions, and discourage investment in technology. Payers are particularly reluctant to fund procedures that lack evidence of cost-effectiveness over time, especially when compared to well-established pharmaceutical therapies. For renal denervation to gain broader acceptance as a routine clinical option, it must demonstrate long-term superiority or complementarity to drug therapy in managing resistant hypertension. Until large-scale, long-duration studies are completed and peer-reviewed, many stakeholders will remain hesitant. Ongoing research and continued post-market surveillance will play a critical role in addressing these concerns, but the current lack of longitudinal evidence remains a barrier to faster adoption. This gap in data not only affects market growth but also influences clinical guidelines and patient access to this potentially transformative therapy.

Key Market Trends

Technology evolution favoring ultrasound and micro-infusion

Technological evolution is playing a central role in the transformation of the global renal denervation market, with a growing shift toward ultrasound and micro-infusion-based systems. While radiofrequency ablation has historically been the standard approach, ultrasound technology is gaining momentum due to its ability to deliver circumferential energy around the arterial wall without requiring direct contact. This feature allows for more uniform nerve ablation and reduces the risk of procedural complications, making it an increasingly attractive option for physicians. The use of ultrasound catheters enables consistent and efficient denervation with shorter procedure times and improved safety profiles. These benefits are particularly important in clinical settings focused on precision and outcomes. Micro-infusion techniques, which involve delivering chemical agents directly into the perivascular space, are also emerging as a promising alternative. This method targets nerve endings with high specificity, allowing for controlled and localized ablation while minimizing damage to surrounding tissues. As companies invest in refining these systems, micro-infusion offers potential advantages for patients who may not be ideal candidates for thermal ablation. The advancement of these technologies is reshaping the competitive landscape, encouraging the development of next-generation devices that combine imaging guidance, real-time feedback, and customizable ablation protocols. With ongoing clinical trials and regulatory interest, ultrasound and micro-infusion platforms are driving innovation and expanding the range of renal denervation options available to physicians. These technologies align with the broader trend in medicine toward less invasive, more targeted interventions that prioritize both efficacy and patient safety. As adoption increases, they are expected to play a key role in elevating the clinical standards for treating resistant hypertension. The transition toward these newer methods reflects a market focused on improving procedural consistency, expanding treatment access, and enhancing long-term outcomes through continuous technological progress.

Key Market Players

• Medtronic Plc.
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• Terumo Corporation
• Johnson & Johnson
• Cordis Corporation
• ReCor Medical, Inc. (Otsuka Holdings)
• Cardiosonic Ltd.
• Mercator MedSystems, Inc.
• Renal Dynamics Limited

Report Scope:

In this report, the Global Renal Denervation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Denervation Market, By Technology:

• Ultrasound Ablation
• Radiofrequency Ablation
• Pharmacologic Ablation
• Microinfusion

Renal Denervation Market, By Product:

• Catheters
• Single Electrode Catheter
• Multi Electrode Catheter
• RF Generator
• Others

Renal Denervation Market, By Therapeutic Area:

• Hypertension
• Heart Failure
• Diabetes
• Renal Failure
• Others

Renal Denervation Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Renal Denervation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Denervation Market.

Available Customizations:

Global Renal Denervation Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Denervation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)
  • 5.2.2. By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)
  • 5.2.3. By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Product
  • 5.3.3. By Therapeutic Area
  • 5.3.4. By End User
  • 5.3.5. By Region

6. North America Renal Denervation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Renal Denervation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Renal Denervation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Renal Denervation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User

7. Europe Renal Denervation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Renal Denervation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Renal Denervation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Renal Denervation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Renal Denervation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Therapeutic Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Renal Denervation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Therapeutic Area
      • 7.3.5.2.4. By End User

8. Asia-Pacific Renal Denervation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Renal Denervation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Renal Denervation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Renal Denervation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Renal Denervation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Therapeutic Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Renal Denervation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Therapeutic Area
      • 8.3.5.2.4. By End User

9. South America Renal Denervation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Renal Denervation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Renal Denervation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Renal Denervation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Middle East and Africa Renal Denervation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Renal Denervation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Therapeutic Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Renal Denervation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Therapeutic Area
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Renal Denervation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Therapeutic Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Medtronic Plc.
  • 13.1.1. Business Overview
  • 13.1.2. Company Snapshot
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Recent Developments
  • 13.1.6. SWOT Analysis
• 13.2. Boston Scientific Corporation
• 13.3. Abbott Laboratories, Inc.
• 13.4. Terumo Corporation
• 13.5. Johnson & Johnson
• 13.6. Cordis Corporation
• 13.7. ReCor Medical, Inc. (Otsuka Holdings)
• 13.8. Cardiosonic Ltd
• 13.9. Mercator MedSystems, Inc
• 13.10. Renal Dynamics Limited

14. Strategic Recommendations

15. About Us & Disclaimer